UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects

European journal of clinical pharmacology, 2005-12, Vol.61 (12), p.873-880

2005

Volltextzugriff (PDF)

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies

Fundamental & clinical pharmacology, 2016-04, Vol.30 (2), p.172-184

2016

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

Journal of clinical pharmacology, 2008-08, Vol.48 (8), p.926-934

2008

Volltextzugriff (PDF)

First Assessment in Humans of the Safety, Tolerability, Pharmacokinetics, and Ex Vivo Pharmacodynamic Antimalarial Activity of the New Artemisinin Derivative Artemisone

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3085-3091

2008

Volltextzugriff (PDF)

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S5-S14

2016

Volltextzugriff (PDF)

How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum

Therapeutic innovation & regulatory science, 2021-05, Vol.55 (3), p.612-618

2021

Volltextzugriff (PDF)

Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S15-S26

2016

Volltextzugriff (PDF)

Variability in clinical chemistry parameters in healthy male volunteers prior to drug administration, an overview of Bayer in-house phase I trials from 2000 - 2013 INSERT TABLE AST and γGT values are less affected. Conclusion: A 24h predose lab sample may

Frontiers in pharmacology, 2017, Vol.8

Wensing, Georg

2017

Volltextzugriff (PDF)

Bioavailability, Pharmacokinetics, and Safety of Riociguat Given as an Oral Suspension or Crushed Tablet with and without Food

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S66-S74

2016

Volltextzugriff (PDF)

Riociguat (BAY 63-2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S35-S42

2016

Volltextzugriff (PDF)

Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women

Pulmonary circulation, 2016-03, Vol.6 (1_suppl), p.S97-S102

2016

Volltextzugriff (PDF)

Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis

International journal of clinical pharmacology and therapeutics, 2021-01, Vol.59 (1), p.1-7

2021

Volltextzugriff (PDF)

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Clinical pharmacology and therapeutics, 2005-10, Vol.78 (4), p.412-421

2005

Volltextzugriff (PDF)

How safe are our studies? Analysis of adverse events in Bayer First-in-Human trials from 2006 to 2016

International journal of clinical pharmacology and therapeutics, 2020-01, Vol.58 (1), p.10-20

2020

Volltextzugriff (PDF)

Cinaciguat (BAY 58―2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

Circulation (New York, N.Y.), 2009-06, Vol.119 (21), p.2781-2788

2009

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Clinical pharmacology: advances and applications, 2014-01, Vol.6 (default), p.51-59

2014

Volltextzugriff (PDF)

First in Human (FiH) studies in healthy volunteers – a 10 years review

Frontiers in pharmacology, 2017, Vol.8

2017

Volltextzugriff (PDF)

Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials

European Journal of Clinical Pharmacology, 2017-04, Vol.73 (4), p.409-416

2017

Volltextzugriff (PDF)

Riociguat (BAY 63-2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study

Journal of clinical pharmacology, 2011-07, Vol.51 (7), p.1051-1060

2011

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers

Journal of clinical pharmacology, 2008-12, Vol.48 (12), p.1400-1410

2008

Volltextzugriff (PDF)

Selective 5-HT1A-R-agonist Repinotan Prevents Remifentanil-induced Ventilatory Depression and Prolongs Antinociception

Anesthesiology (Philadelphia), 2012, Vol.116 (1), p.56-64

2012

Volltextzugriff (PDF)

Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I—Comparison between Healthy Subjects and Patients with Hypertension

Biomarker insights, 2007-01, Vol.2, p.81-93

2007

Volltextzugriff (PDF)

Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs)

International journal of clinical pharmacology and therapeutics, 2014-02, Vol.52 (2), p.143-150

2014

Volltextzugriff (PDF)

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein

British journal of clinical pharmacology, 2012-02, Vol.73 (2), p.210-218

2012

Volltextzugriff (PDF)

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food

BMC pharmacology & toxicology, 2015-09, Vol.16 (S1), p.A82-A82, Article A82

2015

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(62)

Sprache

Englisch
(61)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers

First Assessment in Humans of the Safety, Tolerability, Pharmacokinetics, and Ex Vivo Pharmacodynamic Antimalarial Activity of the New Artemisinin Derivative Artemisone

Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum

Assessment of the Effects of Renal Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63-2521)

Variability in clinical chemistry parameters in healthy male volunteers prior to drug administration, an overview of Bayer in-house phase I trials from 2000 - 2013 INSERT TABLE AST and γGT values are less affected. Conclusion: A 24h predose lab sample may

Bioavailability, Pharmacokinetics, and Safety of Riociguat Given as an Oral Suspension or Crushed Tablet with and without Food

Riociguat (BAY 63-2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study

Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women

Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

How safe are our studies? Analysis of adverse events in Bayer First-in-Human trials from 2006 to 2016

Cinaciguat (BAY 58―2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

First in Human (FiH) studies in healthy volunteers – a 10 years review

Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials

Riociguat (BAY 63-2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers

Selective 5-HT1A-R-agonist Repinotan Prevents Remifentanil-induced Ventilatory Depression and Prolongs Antinociception

Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I—Comparison between Healthy Subjects and Patients with Hypertension

Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs)

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food

Suchergebnisse filtern